2008: Crystal Associated Arthropathies

Crystal Associated Arthropathies

Sunday, October 26, 2008

22

Tophus Response to Pegloticase (PGL) Therapy: Pooled Results from GOUT1 and GOUT2, PGL Phase 3 Randomized, Double Blind, Placebo-controlled Trials

23

MRI and Ultrasound Findings in Patients with Gout and Normal Plain Radiographs

24

The Treatment Of Gout: Results From The Gema Audit Of Clinical Practice

25

Health-Related Quality-of-Life (HRQOL) of Patients with Refractory Gout (Refractory-Gout) and US Veterans Administration Patients with Gout+Comorbities (VA-Gout) is Poor, and Comparable to that in other Severe Chronic Conditions

26

Serum Urate Levels During Acute Gout

27

Improvement in Health-related Quality of Life (HRQL) and Disability Index in Treatment Failure Gout (TFG) after Pegloticase (PGL) Therapy: Pooled Results from GOUT1 and GOUT2, Phase 3, Randomized, Double Blind, Placebo (PBO)-Controlled Trials

28

RDEA594, a Potential Uric Acid Lowering Agent through Inhibition of Uric Acid Reuptake, Shows Better Pharmacokinetics than its Prodrug RDEA806

29

Allopurinol Treatment and Mortality in Hyperuricemic Veterans

30

Not Only A Swollen Big Toe: Hospitalizations For Acute Myocardial Infarction In Patients With Gout In The United States

31

First Series of Etanercept for Prophylaxis and Steroid Sparing for Gout Patients with Renal Insufficiency including Long Term Follow Up

32

Colorimetric Detection of Calcium Phosphate Crystals in Synovial Fluid

33

Neutrophil Function in Human Gouty Arthritis

34

Clinical Homogeneity and Syndromic Characteristics of Treatment Failure Gout (TFG) in Four Independent Cohorts

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>